Toronto Lung Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada; Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.
Toronto Lung Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
J Thorac Cardiovasc Surg. 2018 Mar;155(3):1316-1328.e1. doi: 10.1016/j.jtcvs.2017.09.161. Epub 2017 Nov 22.
Extracorporeal life support (ECLS) is increasingly used to bridge deteriorating patients awaiting lung transplantation (LTx), however, few systematic descriptions of this practice exist. We therefore aimed to review our institutional experience over the past 10 years.
In this case series, we included all adults who received ECLS with the intent to bridge to LTx. Data were retrieved from patient charts and our institutional ECLS and transplant databases.
Between January 2006 and September 2016, 1111 LTx were performed in our institution. ECLS was used in 71 adults with the intention to bridge to LTx; of these, 11 (16%) were bridged to retransplantation. The median duration of ECLS before LTx was 10 days (range, 0-95). We used a single dual-lumen venous cannula in 23 patients (32%). Nine of 13 patients (69%) with pulmonary hypertension were bridged by central pulmonary artery to left atrium Novalung. Twenty-five patients (35%) were extubated while on ECLS and 26 patients (37%) were mobilized. Sixty-three patients (89%) survived to LTx. Survival by intention to treat was 66% (1 year), 58% (3 years) and 48% (5 years). Survival was significantly shorter in patients undergoing ECLS bridge to retransplantation compared with first LTx (median survival, 15 months (95% CI, 0-31) versus 60 months (95% CI, 37-83); P = .041).
In our center experience, ECLS bridge to first lung transplant leads to good short-term and long-term outcomes in carefully selected patients. In contrast, our data suggest that ECLS as a bridge to retransplantation should be used with caution.
体外生命支持(ECLS)越来越多地用于桥接等待肺移植(LTx)的病情恶化的患者,但关于这种治疗方法的系统描述很少。因此,我们旨在回顾过去 10 年的机构经验。
在这个病例系列中,我们纳入了所有接受 ECLS 治疗以桥接 LTx 的成年患者。数据从患者病历和我们的机构 ECLS 和移植数据库中检索。
在 2006 年 1 月至 2016 年 9 月期间,我们机构共进行了 1111 例 LTx。71 例成人接受 ECLS 治疗,目的是桥接 LTx;其中 11 例(16%)桥接进行再移植。LTx 前 ECLS 的中位持续时间为 10 天(范围,0-95)。我们在 23 例患者中使用了单个双腔静脉插管(32%)。13 例肺动脉高压患者中有 9 例(69%)通过中心肺动脉到左心房 Novalung 桥接。25 例(35%)患者在接受 ECLS 治疗时拔管,26 例(37%)患者可活动。63 例(89%)患者存活至 LTx。意向治疗的生存率为 66%(1 年)、58%(3 年)和 48%(5 年)。与首次 LTx 相比,接受 ECLS 桥接再移植的患者生存率明显更短(中位生存时间,15 个月(95%CI,0-31)与 60 个月(95%CI,37-83);P =.041)。
在我们中心的经验中,在仔细选择的患者中,ECLS 桥接首次肺移植可带来良好的短期和长期结果。相比之下,我们的数据表明,ECLS 作为再移植的桥接应谨慎使用。